2019 Keynote Address

Launch your #ADAA2019 experience with an inspiring keynote address:

Potential Drugs of Abuse as Antidepressants and Anxiolytics:  Pluses and Minuses

Thursday, March 28, 2018 - 5:45 -  7:00 pm

Keynote Description

Increasing data from research studies point to potential drugs of abuse as antidepressants and anxiolytics. This presentation reviews recent data and raises key issues regarding how to balance risk-benefit both for individual patients and society at-large.

Biography

Dr. Schatzberg received his MD from New York University. He did his psychiatric residency at Harvard Medical School, Massachusetts Mental Health Center where he was later a Professor of Psychiatry before becoming the Kenneth T. Norris, Jr. Professor and Chair at Stanford. Dr. Schatzberg has been an active investigator in the biology and psychopharmacology of depressive disorders and has authored over 700 publications and abstracts. He has been President of the American College of Neuropsychopharmacology, the Society of Biological Psychiatry, and the American Psychiatric Association, and has received numerous national and international awards.

Dr. Schatzberg - Recent News Stories

New Ketamine-Based Antidepressant Nasal Spray Sparks Criticism, Westsidestory.com, March 22, 2019

FDA May Give A ‘Go Ahead’ To Esketamine For Severe Depression, GlobalNewsJournal.com, March 18, 2019

What Makes the Newly Approved Drug for Depression so Different?, Livescience.com, March 6, 2019

FDA Approves Ketamine-Like Drug for Severe Depression, Healthday.com, March 6, 2019

FDA Poised to Approve Ketamine Like Drug to Ease Depression, Healthday.com, March 5, 2019

"Many say Ketamine Eased their Depression, But is it Safe?

"Seeking the Optimal Dose for Ketamine’s Short-Term Rapid Antidepressant Effects"

"A DNA Test Claims to Tell You How You'll Respond to Depression Medications. Here's What Scientists Think Of It."

"Researchers Discover That Fast-Acting Antidepressant Ketamine Engages the Body’s Opioid System"

"Ketamine Affects the Brain Like an Opioid, Study Finds"

"Ketamine may Produce Antidepressant Effects Through Opioid Receptors"

"Ketamine, A Promising Depression Treatment, Seems To Act Like An Opioid" 

"Stanford Researchers are Figuring out how Ketamine Fights Depression — and Why the Drug has Been Called 'The Most Important Discovery in Half a Century.'"

"Ketamine's Antidepressant Benefits Tied to the Brain's Opioid System"

"Doctors Have Found a Big Problem with Using Ketamine to Treat Depression"

"Ketamine's Antidepressive Effects Tied to Opioid System in Brain"

"Ketamine is emerging as a popular treatment for depression. New research suggests the drug acts like an opioid"

"Ketamine May Ease Depression By Acting Like an Opioid, Study Suggests"

"How Ketamine Treats Depression: It Acts Like an Opioid, Study Suggests"

"FDA Approves New 23andMe Pharmacogenetic Reports, But There Are Some Caveats"

Interested in sponsoring the 2019 Keynote Address? Contact Gabby Oved for more details.

Opening Session Brought to you by Rogers Behavioral Health